Loading
Cancer Research and Treatments · Journal article
Gut Microbes · August 18, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review consolidating preclinical and clinical evidence on the mechanistic role of gut microbiota-mediated amino acid metabolism in cancer. The source identifies dysbiosis-driven alterations in amino acid availability and metabolism as potential drivers of tumorigenesis via effects on inflammation, oxidative stress, and immunity, but acknowledges that significant methodological and conceptual gaps remain, including identification of specific causative strains and characterization of their metabolic pathways.
Journal article. Theoretical; review addresses mechanisms in humans and cancer contexts without specifying a studied cohort..
Alterations in gut microbial composition can lead to imbalances in amino acid availability and metabolism, thereby influencing systemic inflammation, oxidative stress, and immune responses that may promote tumorigenesis. Dysbiosis has been implicated in metabolic disorders, autoimmune conditions, and neurodegenerative diseases, in addition to cancer. Significant challenges remain in identifying specific microbial strains, deciphering their metabolic pathways, and understanding their complex interactions with host factors in cancer progression.
No data on efficacy, safety, or clinical outcomes of microbiome-targeted interventions in cancer patients.
This review frames the gut microbiota as a mechanistic checkpoint and potential therapeutic target in oncology. Clinicians should recognize this as hypothesis-generating synthesis pending rigorous prospective or interventional evidence in cancer populations.
This is a narrative review synthesizing preclinical and clinical evidence on mechanistic relationships between gut microbiota, amino acid metabolism, and cancer, raising questions rather than answering them with primary data.
This review frames the gut microbiota as a mechanistic checkpoint and potential therapeutic target in oncology. Clinicians should recognize this as hypothesis-generating synthesis pending rigorous prospective or interventional evidence in cancer populations.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The gut microbiota plays a crucial role in human health, significantly influencing various physiological functions such as amino acid metabolism, which is essential for maintaining homeostasis and preventing disease. Recent progress in gut microbiota research has highlighted the intricate relationships between gut microbial communities and host amino acid metabolism, particularly in the context of cancer. This review focuses on consolidating the latest advances regarding how gut microbiota-mediated amino acid metabolism contributes to cancer development and progression. While dysbiosis has been implicated in various diseases, such as metabolic disorders, autoimmune conditions, and neurodegenerative diseases, this review specifically examines the evidence linking gut microbiota and amino acid metabolism to cancer. Current studies suggest that alterations in gut microbial composition can lead to imbalances in amino acid availability and metabolism, thereby influencing systemic inflammation, oxidative stress, and immune responses that may promote tumorigenesis. Despite these insights, significant challenges remain, including identifying specific microbial strains, deciphering their metabolic pathways, and understanding their complex interactions with host factors in cancer progression. This review aims to summarize recent preclinical and clinical investigations elucidating the mechanisms linking the gut microbiota, amino acid metabolism, and cancer, and to evaluate potential therapeutic strategies targeting the gut microbiome to modulate amino acid metabolism and improve cancer treatment outcomes. By highlighting the gut microbiota as a promising target for innovative oncological therapies, this review provides insights into microbiome-based interventions targeting amino acid-related pathways in cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.